181 related articles for article (PubMed ID: 24479586)
1. Inhibitory effects of imatinib mesylate on human epidermal melanocytes.
Wang Y; Zhao Y; Liu L; Zhang L; Xiao H; Wu K; Xu Y; Hu Y; Fu H; Cao W; Luo Y; Huang H
Clin Exp Dermatol; 2014 Mar; 39(2):202-8. PubMed ID: 24479586
[TBL] [Abstract][Full Text] [Related]
2. Geniposide enhances melanogenesis by stem cell factor/c-Kit signalling in norepinephrine-exposed normal human epidermal melanocyte.
Lan WJ; Wang HY; Lan W; Wang KY
Basic Clin Pharmacol Toxicol; 2008 Jul; 103(1):88-93. PubMed ID: 18598300
[TBL] [Abstract][Full Text] [Related]
3. Additive effect of heat on the UVB-induced tyrosinase activation and melanogenesis via ERK/p38/MITF pathway in human epidermal melanocytes.
Gu WJ; Ma HJ; Zhao G; Yuan XY; Zhang P; Liu W; Ma LJ; Lei XB
Arch Dermatol Res; 2014 Aug; 306(6):583-90. PubMed ID: 24671267
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate causes hypopigmentation in the skin.
Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
[TBL] [Abstract][Full Text] [Related]
5. Nobiletin, a polymethoxy flavonoid, reduced endothelin-1 plus SCF-induced pigmentation in human melanocytes.
Kim HJ; Yonezawa T; Teruya T; Woo JT; Cha BY
Photochem Photobiol; 2015; 91(2):379-86. PubMed ID: 25488359
[TBL] [Abstract][Full Text] [Related]
6. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
7. Abrogating effect of a xanthophyll carotenoid astaxanthin on the stem cell factor-induced stimulation of human epidermal pigmentation.
Nakajima H; Fukazawa K; Wakabayashi Y; Wakamatsu K; Senda K; Imokawa G
Arch Dermatol Res; 2012 Dec; 304(10):803-16. PubMed ID: 22639095
[TBL] [Abstract][Full Text] [Related]
8. Withaferin A abolishes the stem cell factor-stimulated pigmentation of human epidermal equivalents by interrupting the auto-phosphorylation of c-KIT in human melanocytes.
Terazawa S; Nakajima H; Fukasawa K; Imokawa G
Arch Dermatol Res; 2015 Jan; 307(1):73-88. PubMed ID: 25376854
[TBL] [Abstract][Full Text] [Related]
9. The roles of Frizzled-3 and Wnt3a on melanocyte development: in vitro studies on neural crest cells and melanocyte precursor cell lines.
Chang CH; Tsai RK; Tsai MH; Lin YH; Hirobe T
J Dermatol Sci; 2014 Aug; 75(2):100-8. PubMed ID: 24815018
[TBL] [Abstract][Full Text] [Related]
10. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945
[TBL] [Abstract][Full Text] [Related]
11. Baicalin-induced Akt activation decreases melanogenesis through downregulation of microphthalmia-associated transcription factor and tyrosinase.
Jeong HS; Gu GE; Jo AR; Bang JS; Yun HY; Baek KJ; Kwon NS; Park KC; Kim DS
Eur J Pharmacol; 2015 Aug; 761():19-27. PubMed ID: 25934572
[TBL] [Abstract][Full Text] [Related]
12. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
15. Depigmenting action of platycodin D depends on the cAMP/Rho-dependent signalling pathway.
Jung E; Hwang W; Kim S; Kim YS; Kim YS; Lee J; Park D
Exp Dermatol; 2011 Dec; 20(12):986-91. PubMed ID: 21995379
[TBL] [Abstract][Full Text] [Related]
16. Curcumin inhibits melanogenesis in human melanocytes.
Tu CX; Lin M; Lu SS; Qi XY; Zhang RX; Zhang YY
Phytother Res; 2012 Feb; 26(2):174-9. PubMed ID: 21584871
[TBL] [Abstract][Full Text] [Related]
17. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
Shimizu T; Miyakawa Y; Iwata S; Kuribara A; Tiganis T; Morimoto C; Ikeda Y; Kizaki M
Exp Hematol; 2004 Nov; 32(11):1057-63. PubMed ID: 15539083
[TBL] [Abstract][Full Text] [Related]
18. Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study.
Llamas-Velasco M; Fraga J; Kutzner H; Steegmann JL; García-Diez A; Requena L
J Cutan Pathol; 2014 May; 41(5):417-26. PubMed ID: 24467724
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
[TBL] [Abstract][Full Text] [Related]
20. The role of TC-PTP (PTPN2) in modulating sensitivity to imatinib and interferon-α in CML cell line, KT-1 cells.
Nishiyama-Fujita Y; Shimizu T; Sagawa M; Uchida H; Kizaki M
Leuk Res; 2013 Sep; 37(9):1150-5. PubMed ID: 23759247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
